# Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

> **NCT02753595** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Eribulin mesylate
- **DRUG:** Eribulin mesylate
- **DRUG:** Eribulin mesylate
- **OTHER:** Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)
- **OTHER:** Biologic: PEGylated recombinant human hyaluronidase

## Key facts

- **NCT ID:** NCT02753595
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-13
- **Primary completion:** 2019-08-16
- **Final completion:** 2019-08-16
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** evolving standard of care and difficulties of enrolling participants
- **Last updated:** 2020-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753595, "Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02753595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*